Clinical Trials Browser

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT00005806 2013-06-19

Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer

Phase 1 Completed

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00411047 2013-05-14

Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

34 enrolled

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00068653 2013-04-29

Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer

Phase 2 Completed

27 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00103051 2012-07-16

Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer

Phase 2 Completed

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00217698 2012-06-05

Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

63 enrolled

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00238251 2012-06-05

Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases

Phase 2 Completed

59 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT00193336 2011-05-03

Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00455936 2010-10-25

First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker

Phase 3 Completed

315 enrolled

Thoracic

Adenocarcinoma, Lung Neoplasms

NCT00238628 2010-07-20

A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer

Phase 1/2 Completed

12 enrolled

Thoracic

Lung Neoplasms

NCT00344773 2010-06-29

First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

Phase 2 Completed

46 enrolled 7 charts

Thoracic

Lung Neoplasms, Neoplasm Metastasis

NCT00264498 2009-08-03

Phase II Iressa & Carbo/Gem in NSCLC

Phase 2 Completed

38 enrolled 8 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00256711 2009-04-23

Phase II Iressa Versus Vinorelbine (INVITE)

Phase 2 Completed

192 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00144066 2005-09-02

A Randomized Phase III Trial of Chemotherapy Alone Versus Chemotherapy Followed by Gefitinib in Stage IIIB/IV Non-Small Cell Lung Cancer

Phase 3 Completed

600 enrolled

Thoracic

Lung Neoplasms

Clinical Trials

BM

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

LADIE

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Psychometric Properties of the EORTC QLQ-LC29

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma

High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations

Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)

Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer

Iressa Follow-up Trial

ICARUS

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer

Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer

Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer

Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer

Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases

Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer

First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker

A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer

First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

Phase II Iressa & Carbo/Gem in NSCLC

Phase II Iressa Versus Vinorelbine (INVITE)

A Randomized Phase III Trial of Chemotherapy Alone Versus Chemotherapy Followed by Gefitinib in Stage IIIB/IV Non-Small Cell Lung Cancer